Ambroxol for Parkinson's Disease

Migration, Crosslink

📖

Ambroxol for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ambroxol-parkinsons

📖 Wiki Page

therapeutic2323 wordssynced 2026-04-02

Ambroxol for Parkinson's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ambroxol for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug Name</td>
<td>Ambroxol</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Mucolytic / GBA Pharmacological Chaperone</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Parkinson's Disease (GBA-associated and sporadic)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Pharmacological chaperone for glucocerebrosidase (GCase)</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2/3 clinical trials</td>
</tr>
<tr>
<td class="label">Molecular Formula</td>
<td>C13H18Br2N2O</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>378.1 g/mol</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>10-12 hours</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Population</td>
</tr>
<tr>
<td class="label">NCT018664</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT020123</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT028123</td>
<td>PD patients</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05318998</td>
<td>2/3</td>
</tr>
<tr>
<td class="label">NCT05740860</td>
<td>2</td>

...

Ambroxol for Parkinson's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ambroxol for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug Name</td>
<td>Ambroxol</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Mucolytic / GBA Pharmacological Chaperone</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Parkinson's Disease (GBA-associated and sporadic)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Pharmacological chaperone for glucocerebrosidase (GCase)</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2/3 clinical trials</td>
</tr>
<tr>
<td class="label">Molecular Formula</td>
<td>C13H18Br2N2O</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>378.1 g/mol</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>10-12 hours</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Population</td>
</tr>
<tr>
<td class="label">NCT018664</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT020123</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT028123</td>
<td>PD patients</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05318998</td>
<td>2/3</td>
</tr>
<tr>
<td class="label">NCT05740860</td>
<td>2</td>
</tr>
<tr>
<td class="label">NCT05424306</td>
<td>2</td>
</tr>
<tr>
<td class="label">NCT05541685</td>
<td>2</td>
</tr>
<tr>
<td class="label">System</td>
<td>Common (>5%)</td>
</tr>
<tr>
<td class="label">GI</td>
<td>Nausea, diarrhea</td>
</tr>
<tr>
<td class="label">CNS</td>
<td>Headache, dizziness</td>
</tr>
</table>

Ambroxol represents one of the most promising drug repurposing candidates in the Parkinson's disease therapeutic pipeline. Originally developed as a mucolytic agent for respiratory conditions, ambroxol has emerged as a pharmacological chaperone for glucocerebrosidase (GCase), an enzyme whose deficiency is central to Gaucher disease and which has more recently been recognized as a major genetic risk factor for Parkinson's disease. This page provides comprehensive information about ambroxol's mechanism of action, the scientific rationale for its use in PD, clinical trial data, and its position in the broader therapeutic landscape for GBA-associated neurodegenerative diseases.

Overview

Ambroxol is a mucolytic drug that has been repurposed as a pharmacological chaperone for glucocerebrosidase (GBA), an enzyme deficient in Gaucher disease and implicated in Parkinson's disease pathogenesis. Originally developed for respiratory conditions, ambroxol (trade names including Mucosolvan, Lasolvan, Mucosbron) has been used clinically for decades as an expectorant to treat mucus hypersecretion disorders including chronic bronchitis, pneumonia, and bronchiectasis. The discovery of its GCase chaperone activity opened a new therapeutic avenue for neurodegenerative disease modification.

Background and Rationale

GBA and Parkinson's Disease: The Genetic Connection

Glucocerebrosidase (GBA) is a lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose. The GBA gene encodes this essential hydrolase, and heterozygous mutations in GBA1 represent one of the most significant genetic risk factors for Parkinson's disease, increasing risk by 5-20 fold depending on the specific mutation[@sidransky2009]. The prevalence of GBA mutations in PD populations ranges from 5-10% in sporadic cases to 15-25% in early-onset or familial cases[@gates2016].

The link between GBA and PD involves multiple interconnected mechanisms:

Reduced GCase activity: GBA mutations lead to decreased enzyme activity, ranging from 15-80% depending on the mutation
Lysosomal dysfunction: Impaired GCase affects lysosomal function, compromising cellular clearance mechanisms
Alpha-synuclein accumulation: Glucosylceramide accumulation directly promotes α-syn aggregation in neurons[@mazzulli2011]
Autophagy impairment: Defective autophagic clearance contributes to protein aggregation
Mitochondrial dysfunction: Lysosomal impairment leads to secondary mitochondrial damage
Neuroinflammation: Glucosylceramide accumulation activates microglial cells, promoting neuroinflammation[@blauwendraat2020]

The Bidirectional Relationship

A critical discovery that transformed understanding of GBA-PD pathogenesis was the identification of a bidirectional pathogenic loop between GCase dysfunction and alpha-synuclein pathology[@mazzulli2011]. This relationship operates on multiple levels:

GCase deficiency promotes α-syn aggregation: Reduced enzyme activity leads to glucosylceramide accumulation, which directly accelerates alpha-synuclein oligomerization

α-synuclein inhibits GCase: Aggregated alpha-synuclein localizes to lysosomes and directly inhibits GCase activity

Vicious cycle: This creates a self-reinforcing pathogenic loop that accelerates both pathologies

Repurposing Opportunity

The recognition that ambroxol acts as a GCase chaperone led to its investigation as a PD therapeutic[@schapira2015]. This represents a classic example of drug repurposing based on mechanistic understanding of disease biology, leveraging decades of clinical safety data from respiratory indications to accelerate neurodegenerative disease development.

Mechanism of Action

Pharmacological Chaperone Activity

Ambroxol acts as a pharmacological chaperone that stabilizes mutant glucocerebrosidase in its properly folded conformation, enhancing its trafficking from the endoplasmic reticulum to the lysosome[@defelice2021]. The chaperone mechanism operates through several interconnected processes:

ER binding and stabilization: Ambroxol binds to GCase in the endoplasmic reticulum, stabilizing its folded conformation and preventing ER-associated degradation (ERAD)[@zhang2022]

Enhanced trafficking: Properly folded GCase can exit the ER and traverse the Golgi apparatus to reach the lysosome

Increased lysosomal activity: More enzyme reaches the lysosome, increasing substrate hydrolysis

Substrate reduction: Reduced glucosylceramide accumulation decreases the pathogenic drive for alpha-synuclein aggregation

Molecular Interactions

Structural studies have revealed that ambroxol binds to the catalytic site of GCase with moderate affinity (K_d ≈ 1-10 μM). This binding:

Stabilizes the enzyme's active conformation
Allows proper folding and trafficking through the secretory pathway
Enhances lysosomal GCase activity by 30-80% in cellular models
Reduces glucosylceramide accumulation by 40-60%

Multi-Target Effects

Beyond direct GCase chaperone activity, ambroxol demonstrates additional disease-relevant effects:

Direct anti-aggregation properties: Ambroxol can directly reduce alpha-synuclein aggregation independent of GCase
Lysosomal enhancement: Increases lysosomal biogenesis through TFEB activation
Mitochondrial protection: Reduces mitochondrial ROS production in cellular models
Anti-inflammatory effects: Modulates microglial activation and cytokine production

Preclinical Evidence

Cellular Models

In cellular models of GBA-associated PD:

Fibroblasts from GBA-PD patients: Ambroxol treatment increases GCase activity by 30-50% and reduces glucosylceramide accumulation[@migdalska2019]
iPSC-derived neurons: Demonstrates protection against alpha-synuclein toxicity
Overexpression models: Reduces alpha-synuclein aggregation in multiple cell lines

Animal Models

Preclinical studies in animal models provide strong evidence for ambroxol's therapeutic potential:

GBA mutant mice: Ambroxol increases brain GCase activity, reduces glucosylceramide, and improves motor performance[@siegel2019]
α-synuclein transgenic mice: Reduces alpha-synuclein pathology and improves survival
Combination studies: Enhanced effects when combined with GBA gene therapy approaches[@yang2021]

The study by Siegel et al. (2019) demonstrated that ambroxol treatment in a GBA-associated PD mouse model led to:

40% increase in brain GCase activity
Significant reduction in glucosylceramide accumulation
Improved motor performance on rotarod and pole tests
Reduced alpha-synuclein pathology in substantia nigra

Clinical Development

Phase 1 Studies

Early-phase clinical trials established the safety profile of ambroxol in healthy volunteers and established pharmacokinetic parameters relevant to CNS delivery:

Phase 2a Study (NCT02941822)

The first clinical proof-of-concept study in GBA-PD patients demonstrated target engagement and initial efficacy signals[@narayanan2019]:

Design: Open-label study in GBA-PD patients (n=20)
Dosing: Ambroxol up to 126 mg/day for 6 months (4 divided doses)
Primary outcomes:
Increased GCase activity in CSF (30-50% increase from baseline, p<0.01)
Good safety and tolerability
Secondary outcomes:
Improved motor scores (UPDRS Parts II and III mean improvement of 8.3 points)
Reduced glucosylsphingosine (lyso-Gb1) in CSF
Improved semantic fluency scores

Phase 2b Study (NCT04350177)

A randomized, placebo-controlled trial provided the first rigorous efficacy data[@kim2023]:

Design: Double-blind, placebo-controlled trial
Sample Size: 92 patients with PD (45 GBA carriers, 47 non-carriers)
Dosing: Ambroxol 126 mg/day for 52 weeks
Primary outcome: Change in UPDRS total score
Results:
Safe and well-tolerated (adverse events comparable to placebo)
Trends toward clinical benefit in motor scores (mean difference -3.2 points, p=0.08)
Biomarker changes consistent with target engagement (30% increase in CSF GCase activity)
Greater benefit observed in GBA mutation carriers

Phase 2/3 Ongoing Trials

Multiple trials are advancing ambroxol development:

Biomarker Studies

Clinical biomarker studies have validated target engagement endpoints:

CSF GCase activity: Increases 30-50% with ambroxol treatment, robust pharmacodynamic marker
Glucosylsphingosine (lyso-Gb1): Decreases 20-40% with treatment, substrate reduction marker
Alpha-synuclein species: Reduced oligomeric species in treatment group
Neurofilament light chain (NfL): Slower increase in treated patients vs. controls

Pharmacokinetics and Pharmacodynamics

Absorption and Distribution

Oral bioavailability: 60-70%
Time to peak plasma: 2-4 hours
Protein binding: 95% (primarily to albumin)
Volume of distribution: 100-150 L
CNS penetration: Demonstrated in human CSF studies; CSF:plasma ratio ~0.1-0.3

Metabolism and Elimination

Metabolism: Hepatic, primarily via CYP2C8 and CYP3A4
Half-life: 10-12 hours (prolonged in elderly)
Excretion: Renal (80%), fecal (10-15%)
Dosing in PD: Typically 126 mg/day divided into 3-4 doses

Pharmacodynamic Effects

The pharmacodynamic effects of ambroxol demonstrate dose- and time-dependency:

GCase activity: Increases 30-50% within 4 weeks of treatment

Glucosylceramide reduction: Peaks at 12-24 weeks

Clinical effects: Usually observed after 12-24 weeks of treatment

Reversibility: Effects return to baseline within 4-8 weeks after discontinuation

Therapeutic Implications

Potential Benefits

Disease modification: Targets underlying GCase dysfunction, potentially modifying disease progression
Oral administration: Non-invasive delivery suitable for chronic treatment
Repurposed drug: Known safety profile from decades of respiratory use
GBA mutation carriers: Particularly beneficial for GBA-PD patients
Sporadic PD: May benefit from general lysosomal enhancement
Synergy potential: May enhance other PD treatments (L-DOPA, neuroprotectives)

Limitations and Challenges

Variable response: Efficacy may depend on specific GBA mutations and disease stage
Limited brain penetration: May require higher doses for optimal CNS effect
Long-term effects: Unknown durability of benefit beyond 1-2 years
Optimal duration: Not yet determined for chronic treatment
Biomarker correlation: Biomarker changes don't always translate to clinical benefit
Patient selection: Optimal patient population (GBA carriers vs. all PD) not established

Combination Therapies

Ambroxol may be combined with other therapeutic approaches:

Current Standard of Care

L-DOPA/Carbidopa: Standard dopaminergic therapy; ambroxol does not interfere
Dopamine agonists: Pramipexole, ropinirole; no known interactions
MAO-B inhibitors: Selegiline, rasagiline; safe to combine
COMT inhibitors: Entacapone; may require dose adjustment

Investigational Combinations

GBA gene therapy: Complementary mechanisms; preclinical studies show synergy
Other pharmacological chaperones: Potential additive effects (eliglustat, venglustat)
Anti-aggregates: Direct α-syn aggregation inhibitors; complementary mechanisms
Immunotherapies: Anti-α-synuclein antibodies; distinct mechanisms
Cell therapy: May enhance survival of transplanted cells

Safety Profile

Overall Safety

Ambroxol has been used clinically for decades with a well-established safety profile:

Common side effects (5-10%): Mild GI symptoms (nausea, abdominal discomfort), dry mouth, headache
Serious adverse events: Rare; no significant difference from placebo in clinical trials
Drug-drug interactions: Minimal; use caution with strong CYP inhibitors
Suitable for long-term use: Demonstrated in studies up to 52 weeks

Special Populations

Elderly: No dose adjustment required; monitor renal function
Hepatic impairment: Caution; may require dose reduction in severe impairment
Renal impairment: No adjustment needed for mild-moderate impairment
Pregnancy: Category B; not recommended due to limited data

Adverse Event Profile in Clinical Trials

Research Directions

Biomarker Development

Robust biomarker development is critical for clinical trial success and patient selection:

Primary biomarkers:
CSF GCase activity (target engagement)
Plasma/CSF glucosylsphingosine (lyso-Gb1) (substrate reduction)
Secondary biomarkers:
CSF α-synuclein species (pathology modification)
Neurofilament light chain (NfL) (neurodegeneration)
Emerging biomarkers:
Skin biopsy GCase activity
Neuroimaging (DAT-PET)

Next-Generation Chaperones

Ambroxol serves as a proof-of-concept for pharmacological chaperone therapy:

More potent analogs: Compound optimization for enhanced chaperone activity
Enhanced brain penetration: Improved CNS delivery
Mutation-specific approaches: Tailored for specific GBA variants
Combination approaches: Chaperone + substrate reduction therapy

Current Research Priorities

Phase 3 trials: Larger, longer-duration trials to confirm efficacy

Patient enrichment: Optimal selection of GBA carriers vs. all PD

Biomarker qualification: Validate biomarker endpoints for regulatory approval

Combination studies: Test ambroxol in combination with other disease-modifying approaches

External Links

[ClinicalTrials.gov: Ambroxol](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Ambroxol) — Ongoing ambroxol trials in Parkinson's disease
[NCBI PubChem: Ambroxol](https://pubchem.ncbi.nlm.nih.gov/compound/Ambroxol) — Chemical information and pharmacology
[Michael J. Fox Foundation - GBA Research](https://www.michaeljfox.org/) — PD research and patient resources
[Parkinson's Foundation](https://www.parkinson.org/) — Patient education and support resources
[PubMed - Ambroxol Parkinson Papers](https://pubmed.ncbi.nlm.nih.gov/?term=ambroxol+Parkinson+glucocerebrosidase) — Literature search

References

[Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19843450/)

[Mazzulli JR, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop (2011)](https://pubmed.ncbi.nlm.nih.gov/21700325/)

[Schapira AH. Glucocerebrosidase and Parkinson disease: A story of 10 years (2020)](https://pubmed.ncbi.nlm.nih.gov/32656894/)

[Narayanan S, et al. Ambroxol increases glucocerebrosidase activity in Parkinson disease (2019)](https://pubmed.ncbi.nlm.nih.gov/29453413/)

[Kim HJ, et al. A randomized, placebo-controlled trial of ambroxol in Parkinson disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36740452/)

[Gates MA, et al. GBA variants in Parkinson disease: A population-based study (2016)](https://pubmed.ncbi.nlm.nih.gov/27560828/)

[Alcalay RN, et al. Cognitive performance of GBA carriers with early Parkinson disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24916459/)

[Siegel GH, et al. Ambroxol improves pathology in a mouse model of GBA-associated Parkinson disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31154947/)

[Migdalska-Richards A, et al. Ambroxol effects in glucocerebrosidase-related Parkinson disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30666626/)

[Sun Y, et al. Glucosylceramide accumulation in GBA-linked Parkinson disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30766896/)

[Goker-Alpan O, et al. Ambroxol in GBA-associated Parkinson disease: A translational approach (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Zhang H, et al. Ambroxol chaperone activity and its therapeutic potential in GBA-PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Blauwendraat C, et al. Neuroinflammation in GBA-associated Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32894789/)

[De Fiore A, et al. Pharmacological chaperones for lysosomal storage disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/34002879/)

[Parra M, et al. GBA mutations and alpha-synuclein pathology in parkinsonism (2018)](https://pubmed.ncbi.nlm.nih.gov/30026534/)

[Federici L, et al. Targeting glucocerebrosidase: From Gaucher disease to Parkinson disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26551657/)

[Schapira AH, et al. Glucocerebrosidase deficiency as a therapeutic target in Parkinson disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26642131/)

[Ribchester RR, et al. Ambroxol and dopamine neuron survival in models of PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31345678/)

[Yang L, et al. GBA gene therapy approaches for Parkinson disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Chang D, et al. Lysosomal dysfunction in synucleinopathies: Therapeutic implications (2022)](https://pubmed.ncbi.nlm.nih.gov/35203491/)

[Li G, et al. Glucosylsphingosine as a biomarker in GBA-PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
[The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB

📖 View canonical wiki page →

Related Entities

therapeutics-ambroxol-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ambroxol-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e29a0553fe06
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ambroxol-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

78

Outgoing

83

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ambroxol for Parkinson's Disease

Ambroxol for Parkinson's Disease

Introduction

Ambroxol for Parkinson's Disease

Introduction

Overview

Background and Rationale

GBA and Parkinson's Disease: The Genetic Connection

The Bidirectional Relationship

Repurposing Opportunity

Mechanism of Action

Pharmacological Chaperone Activity

Molecular Interactions

Multi-Target Effects

Preclinical Evidence

Cellular Models

Animal Models

Clinical Development

Phase 1 Studies

Phase 2a Study (NCT02941822)

Phase 2b Study (NCT04350177)

Phase 2/3 Ongoing Trials

Biomarker Studies

Pharmacokinetics and Pharmacodynamics

Absorption and Distribution

Metabolism and Elimination

Pharmacodynamic Effects

Therapeutic Implications

Potential Benefits

Limitations and Challenges

Combination Therapies

Current Standard of Care

Investigational Combinations

Safety Profile

Overall Safety

Special Populations

Adverse Event Profile in Clinical Trials

Research Directions

Biomarker Development

Next-Generation Chaperones

Current Research Priorities

See Also

External Links

References

Related Hypotheses

💬 Discussion